Skip to main content

Table 1 Baseline characteristics of patients sampled for lumefantrine pharmacokinetics.

From: Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

Variable

Supervised arm

Unsupervised arm

 

< 5 years

5–14 years

≥15 years

< 5 years

5–14 years

≥15 years

number sampled

70

92

79

68

91

79

sex ratio (M/F)

1.9 (46/24)

0.9 (43/49)

0.8 (36/43)

1.1 (36/32)

0.7 (37/54)

0.5 (28/51)

median age (range)

3 (1–4)

7 (5–14)

25 (15–60)

3 (1–4)

8 (5–14)

25 (15–80)

parasite density (median, IQR)

12 344 (4232–33 799)

15 668 (3750–36523)

6256 (1957–15 980)

22 777 (11 290–51 775)

11 367 (3449–32 475)

6156 (2749–19 459)

axillary temperature (°C) (mean, IQR)

37.5 (36.7–38.4)

37.3 (36.4–38.0)

36.7 (36.0–37.5)

37.7 (36.7–38.9)

37.1 (36.1–37.8)

36.7 (36.1–37.2)

weight-adjusted lumefantrine dose (mg/Kg) (mean, range)

66 (48–96)

72 (48–96)

53 (32–76)

68 (48–96)

73 (51–96)

54 (35–80)